NASDAQ:TTNP - Titan Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$1.52
▲ +0.13 (9.35%)

This chart shows the closing price for TTNP by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Titan Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TTNP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TTNP

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Titan Pharmaceuticals in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $1.52.

This chart shows the closing price for TTNP for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 1 polled investment analysts is to hold stock in Titan Pharmaceuticals.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/22/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/23/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/21/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/19/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/17/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/18/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/17/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/16/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/26/2022Maxim GroupDowngradeHoldMedium
2/18/2021Maxim GroupUpgradeHold ➝ Buy$11.00High
8/14/2020Maxim GroupDowngradeBuy ➝ Hold$30.00High
6/25/2020Maxim GroupInitiated CoverageBuy$30.00Medium
4/1/2020Maxim GroupInitiated CoverageBuy$30.00Medium
11/15/2019Maxim GroupReiterated RatingBuy$30.00Low
10/23/2019Maxim GroupUpgradeHold ➝ Buy$30.00High
8/15/2019Maxim GroupDowngradeBuy ➝ HoldHigh
6/26/2019Maxim GroupInitiated CoverageBuy ➝ Buy$120.00High
4/3/2018Roth CapitalSet Price TargetHold$360.00Low
11/10/2017Roth CapitalDowngradeBuy ➝ Neutral$1,080.00 ➝ $360.00N/A
10/5/2017Roth CapitalReiterated RatingBuy$1,080.00N/A
(Data available from 8/16/2017 forward)

News Sentiment Rating

0.25 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/17/2022
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/16/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/18/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/17/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/17/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/16/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
7/16/2022
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/15/2022

Current Sentiment

  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Titan Pharmaceuticals logo
Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in Canada and the European Union. It is also developing kappa opioid agonist peptide program (TP-2021) for use in combination with ProNeura technology for the treatment of chronic pruritus; nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder; and other programs, including HIV preventative therapeutic and a contraceptive from a single ProNeura implant for women and adolescent girls. The company was incorporated in 1992 and is based in South San Francisco, California.
Read More

Today's Range

Now: $1.52
Low: $1.36
High: $1.54

50 Day Range

MA: $1.00
Low: $0.46
High: $1.52

52 Week Range

Now: $1.52
Low: $0.35
High: $2.38

Volume

222,230 shs

Average Volume

108,264 shs

Market Capitalization

$22.24 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.18

Frequently Asked Questions

What sell-side analysts currently cover shares of Titan Pharmaceuticals?

The following Wall Street research analysts have issued stock ratings on Titan Pharmaceuticals in the last twelve months: Maxim Group, and StockNews.com.
View the latest analyst ratings for TTNP.

What is the current price target for Titan Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Titan Pharmaceuticals in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Titan Pharmaceuticals in the next year.
View the latest price targets for TTNP.

What is the current consensus analyst rating for Titan Pharmaceuticals?

Titan Pharmaceuticals currently has 1 hold rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in TTNP, but not buy more shares or sell existing shares.
View the latest ratings for TTNP.

What other companies compete with Titan Pharmaceuticals?

How do I contact Titan Pharmaceuticals' investor relations team?

Titan Pharmaceuticals' physical mailing address is 400 OYSTER POINT BLVD SUITE 505, SAN FRANCISCO CA, 94080. The specialty pharmaceutical company's listed phone number is (650) 244-4990 and its investor relations email address is [email protected] The official website for Titan Pharmaceuticals is www.titanpharm.com. Learn More about contacing Titan Pharmaceuticals investor relations.